Document:

EX-10.7

 Exhibit 10.7 

ARTIVA BIOTHERAPEUTICS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or
consultant to Artiva Biotherapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the
Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any
portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the
sole discretion of the Board or the Compensation Committee of the Board. 
 Annual Cash Compensation 

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of
each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service
and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 
  

	1.	 Annual Board Service Retainer: 

 

	 	a.	 All Eligible Directors: $35,000 

 

	 	b.	 Independent Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000

  

	2.	 Annual Committee Chair Service Retainer: 

 

	 	a.	 Chair of the Audit Committee: $15,000 

 

	 	b.	 Chair of the Compensation Committee: $10,000 

 

	 	c.	 Chair of the Nominating and Corporate Governance Committee: $10,000 

 

	 	d.	 Chair of the Science and Technology Committee: $10,000 

 

	3.	 Annual Committee Member Service Retainer (not applicable to Committee Chairs): 

 

	 	a.	 Member of the Audit Committee: $7,500 

 

	 	b.	 Member of the Compensation Committee: $5,000 

 

	 	c.	 Member of the Nominating and Corporate Governance Committee: $5,000 

 

	 	d.	 Member of the Science and Technology Committee: $5,000 

  
 1. 

 Equity Compensation 

The equity compensation set forth below will be granted under the Company’s 2022 Equity Incentive Plan (the “Plan”), subject to
the approval of the Plan by the Company’s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the
underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than
for death, Disability or Cause (as each such term is defined in the Plan), the post-termination exercise period will be [        ] months from the date of termination). 

1.    Initial Grant: For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the
date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by
the Board or the Compensation Committee of the Board, granted a stock option to purchase [                ] shares of Common Stock (the “Initial
Grant”). The shares subject to each Initial Grant will vest [                ], subject to the Eligible Director’s Continuous Service (as defined in
the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan). 
 2.    Annual
Grant: On the date of each annual stockholder meeting of the Company held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such
stockholder meeting will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase
[                ] shares of Common Stock (the “Annual Grant”). The shares subject to the Annual Grant will vest in full on the earlier of the
date that is 12 months following the grant date thereof or the date of the Company’s next annual stockholder meeting, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date and will vest in
full upon a Change in Control (as defined in the Plan). 

  
 2.EX-10.26

 Exhibit 10.26 

October 15, 2021 
 VIA EMAIL

 Thomas J. Farrell 
 Founder & Chief Strategy
Officer 
 Re: Separation Agreement 
 Dear Tom: 

This letter sets forth the substance of our agreement (the “Agreement”) regarding your transition and separation from
Artiva Biotherapeutics, Inc. (the “Company”). This Agreement will become effective only upon the Effective Date specified in Section 9 below. 

1.    Separation. Your employment from any and all employment and officer positions you hold or have held
with the Company shall cease effective October 15, 2021 (the “Separation Date”), which will be your last day of employment with the Company. 

2.    Accrued Wages and Vacation. On the Separation Date, the Company will pay you all accrued wages, and
all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to these payments regardless of whether or not you sign this Agreement. 

3.    Severance Benefits. If you: (i) timely sign and return this Agreement to the Company on or within
twenty-one (21) days after the Separation Date; (ii) allow the releases contained herein to become effective; (iii) remain available after your Separation Date to answer any questions from the
Company regarding your previous job duties; and (iv) comply with all of your legal and contractual obligations to the Company, then in full satisfaction of your Employment Agreement dated March 1, 2019 (as amended on June 17. 2020 and
December 18, 2020 (the “Employment Agreement”), the Company will provide you with the following severance benefits (the “Severance Benefits”): 

a.     Severance Payment. The Company will pay you, as severance, a lump sum amount equal to eighteen
(18) months of your current base salary (the “Salary Severance Payment”). The Salary Severance Payment will be paid to you on the Company’s first regularly scheduled payroll date after the Effective Date. You also
will receive a prorated amount of your target Annual Performance Bonus for 2021, subject to standard payroll deductions and withholdings (the “Severance Bonus”). The Severance Bonus will be paid in a lump sum, less applicable
payroll withholdings and deductions, on the later of (x) the same schedule as Annual Bonuses are paid to the Company’s other executive officers and (y) on the first regularly scheduled payroll date after the Effective Date. 

b.     Equity Acceleration and Extension of Exercise Period. You were granted options to purchase an aggregate of
545,000 shares of the Company’s common stock (the “Options”) under the Company’s 2020 Equity Incentive Plan (the “Plan”). As an additional benefit, the Company will accelerate the vesting on
100% of your outstanding Options that are 

 
subject to time-based vesting requirements that are unvested as of the Separation Date, such that those shares will be deemed fully vested and exercisable in accordance with their terms as of the
Separation Date. In addition, the exercise period applicable to 375,000 of the Options ( the “375,000 Options“) shall be extended so that you have eighteen (18) months after the Separation Date to exercise the 375,000 Options
(including, for avoidance of doubt, any portion of such 375,000 Options that became vested as a result of the foregoing accelerated vesting benefit) (the “Extended Exercise Period”), subject to the terms of the Plan. Except for the
foregoing accelerated vesting and Extended Exercise Period benefits, all existing terms and conditions applicable to the Options shall remain in full force and effect (including the ability to early exercise 85,000 of the Options as previously
approved by the Board). The Extended Exercise Period benefit may convert the 375,000 Options that were previously incentive stock options into non-statutory stock options. Pursuant to tax rules, any Equity
Awards that you hold which are “incentive stock options” under Section 422 of the Internal Revenue Code of 1986, as amended, shall cease to qualify as “incentive stock options” on the date three (3) months following
your Separation Date. You are advised by the Company to seek independent legal advice with respect to tax and securities law issues regarding your Options. 

c.     Health Insurance; COBRA. To the extent provided by the federal COBRA law or, if applicable, state insurance
laws, and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense. Later, you may be able to convert to an individual policy through the provider of the
Company’s health insurance, if you wish. If you timely elect continued coverage under COBRA, the Company will pay for the COBRA premiums to continue your health insurance coverage (including coverage for eligible dependents, if applicable)
(“COBRA Premiums”) through the period (the “COBRA Premium Period”) starting on the Separation Date and ending on the earliest to occur of: (i) the last day of the eighteenth (18th) month following the Separation Date; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA
continuation coverage for any reason. You must timely pay your premiums, and then provide the Company with proof of same to obtain reimbursement for your COBRA premiums under this Section. In the event you become covered under another
employer’s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion,
that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay you, on the first day of each calendar
month, a fully taxable cash payment equal to the applicable COBRA premiums for that month for the remainder of the COBRA Premium Period, which you may (but are not obligated to) use toward the cost of COBRA premiums. 

4.    No Other Compensation or Benefits. You acknowledge that, except as expressly provided in this
Agreement, you have not earned, and will not earn by the Separation, and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance or benefits before or after the
Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account). 

  
 2. 

 5.    Expense Reimbursements. You agree that, no later
than thirty (30) days following the Separation Date, you will submit your final documented employee expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek
reimbursement. All claims for reimbursement shall be submitted by documented business expense report upon Company-approved forms and shall include receipts. The Company will reimburse you for these expenses pursuant to its regular business practice.

 6.    Return of Company Property. You agree that on the Separation Date, you will return to the
Company all Company documents (and all copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, correspondence, memoranda, notes, notebooks, drawings, books and records, plans,
forecasts, reports, proposals, studies, agreements, financial information, personnel information, sales and marketing information, research and development information, systems information, specifications, computer-recorded information, tangible
property and equipment, credit cards, entry cards, identification badges and keys; and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part)
(“Company Property”); provided, however, that the foregoing shall not apply to information and documentation you received solely in your capacity as a member of the Board, or as a stockholder, option holder or restricted
stock unit holder of the Company. You agree to perform a good faith search to ensure that you are no longer in possession or control of any Company Property after the Separation Date. Your timely compliance with this paragraph is a condition
precedent to your receipt of the Severance Benefits described above. 
 7.    Release of Claims. 

a.     General Release. In exchange for the consideration provided to you under this Agreement, you hereby generally
and completely release the Company and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, members, partners, agents, attorneys, predecessors, successors, parent
and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to
events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”). 

b.     Scope of Release. The Released Claims include, but are not limited to: (1) all claims arising out of or
in any way related to your employment with the Company or service on the Board or the termination of that employment or service; (2) all claims related to your compensation or benefits from the Company, including, but not limited to, salary,
bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the
implied covenant of good faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local
statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the
federal Age Discrimination in Employment Act of 1967 (“ADEA”). 

  
 3. 

 c.     Excluded Claims and Protected Rights. The claims described
above that you are releasing do not include: (1) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are a party, the charter or bylaws of the Company, or under
applicable law; (2) any rights which cannot be waived as a matter of law; or (3) any claims arising from breach of this Agreement. Nothing in this Agreement prevents you from filing a charge or complaint with the Equal Employment
Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (collectively, the
“Government Agencies”). You understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government
Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and
agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement. You represent and
warrant that you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims. 

8.    Waiver of Unknown Claims. In giving the releases set forth in this Agreement, which include claims
which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims that the creditor or releasing
party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” You hereby expressly
waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to your release of claims herein, including but not limited to the release of unknown and unsuspected
claims. 
 9.    ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing
any rights you may have under ADEA, and that the consideration given for the waiver and release in the preceding paragraph is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised by
this writing that: (a) your waiver and release do not apply to any rights or claims that may arise after the date you sign this Agreement; (b) you should consult with an attorney prior to executing this Agreement (although you may choose
voluntarily not to do so); (c) you have twenty-one (21) days after the date of your receipt of this Agreement to consider this Agreement (although you may choose to voluntarily execute this Agreement
earlier); (d) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (by providing written notice of your revocation to me); and (e) this Agreement will not be effective until the eighth (8th) day after you sign this Agreement, provided the revocation period has expired without your having revoked (the “Effective Date”), and you will not receive the benefits
specified by this Agreement unless and until it becomes effective. 

  
 4. 

 10.    Continuing Obligations. You acknowledge and
reaffirm your continuing obligations under your signed Confidential Information and Invention Assignment Agreement, attached hereto as Exhibit A and which is incorporated herein by reference, and agree to abide by those continuing
obligations. 
 11.    Representations. You hereby represent that you have been paid all compensation owed
and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise, and have not suffered any on-the-job injury for which you have not already filed a workers’ compensation claim. 

12.    Miscellaneous. This Agreement, together with the continuing obligations under the Employment
Agreement and documents referenced herein, constitute the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter. It is entered into without reliance on any promise or
representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and an
authorized member of the Board. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. The Company
may freely assign this Agreement, without your prior written consent. You may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written consent of the Company. The failure to enforce any breach
of this Agreement shall not be deemed to be a waiver of any other or subsequent breach. For purposes of construing this Agreement, any ambiguities shall not be construed against either party as the drafter. If any provision of this Agreement is
determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable in a manner consistent with the
intent of the parties insofar as possible. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California without regard to conflict of laws principles. This
Agreement may be executed in counterparts or with facsimile signatures, which shall be deemed equivalent to originals. 
 Signature Page
Follows. 

  
 5. 

 If this Agreement is acceptable to you, please sign below and return one original to me. 

I wish you all the best in your future endeavors. 
 Sincerely,

  

			
	Artiva Biotherapeutics, Inc.
		
	By:	 	 /s/ Fred Aslan

	Name:	 	Fred Aslan
	Title:	 	Chief Executive Officer

  

	
	AGREED AND ACCEPTED:
	
	 /s/ Thomas J. Farrell

	Thomas J. Farrell
	Founder & Chief Strategy Officer
	
	Date: October 15, 2021

 Signature page to Separation Agreement. 

  
 6.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]